Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
Arbutus Biopharma (Nasdaq: ABUS) has announced it will release its third quarter 2024 financial results and provide a corporate update on Wednesday, November 6, 2024. The company will issue a press release at 7:30 a.m. ET, followed by a conference call and webcast at 8:45 a.m. ET. Arbutus is a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) through its pipeline of compounds, including the RNAi therapeutic imdusiran and oral PD-L1 inhibitor AB-101.
Arbutus Biopharma (Nasdaq: ABUS) ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 e fornirà un aggiornamento aziendale mercoledì 6 novembre 2024. L'azienda emetterà un comunicato stampa alle 7:30 ora orientale, seguito da una conferenza telefonica e da un webcast alle 8:45 ora orientale. Arbutus è una società biofarmaceutica in fase clinica focalizzata sullo sviluppo di una cura funzionale per il virus dell'epatite B cronica (cHBV) attraverso il suo portafoglio di composti, tra cui il terapeutico RNAi imdusiran e l'inibitore orale PD-L1 AB-101.
Arbutus Biopharma (Nasdaq: ABUS) ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 y proporcionará una actualización corporativa el miércoles 6 de noviembre de 2024. La compañía emitirá un comunicado de prensa a las 7:30 a.m. ET, seguido de una conferencia telefónica y una transmisión en vivo a las 8:45 a.m. ET. Arbutus es una empresa biofarmacéutica en etapa clínica centrada en desarrollar una cura funcional para el virus de la hepatitis B crónica (cHBV) a través de su cartera de compuestos, incluidos el terapéutico de RNAi imdusiran y el inhibidor oral de PD-L1 AB-101.
Arbutus Biopharma (Nasdaq: ABUS)는 2024년 11월 6일 수요일에 2024년 3분기 재무 결과를 발표하고 회사 업데이트를 제공할 것이라고 발표했습니다. 이 회사는 동부 표준시 7:30에 보도 자료를 발행하고, 8:45에 전화 회의 및 웹캐스트를 진행할 예정입니다. Arbutus는 RNAi 치료제 imdusiran과 경구용 PD-L1 억제제 AB-101을 포함한 화합물 파이프라인을 통해 만성 B형 간염 바이러스(cHBV)에 대한 기능적 치료제를 개발하는 데 초점을 맞춘 임상 단계의 생명공학 회사입니다.
Arbutus Biopharma (Nasdaq: ABUS) a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 et fournira une mise à jour de l'entreprise le mercredi 6 novembre 2024. La société publiera un communiqué de presse à 7h30 HE, suivi d'une conférence téléphonique et d'un webinaire à 8h45 HE. Arbutus est une entreprise biopharmaceutique en phase clinique axée sur le développement d'un traitement fonctionnel pour le virus de l'hépatite B chronique (cHBV) à travers son pipeline de composés, y compris le thérapeutique RNAi imdusiran et l'inhibiteur oral PD-L1 AB-101.
Arbutus Biopharma (Nasdaq: ABUS) hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal 2024 veröffentlichen und am Mittwoch, den 6. November 2024, ein Unternehmensupdate bereitstellen wird. Das Unternehmen wird um 7:30 Uhr ET eine Pressemitteilung veröffentlichen, gefolgt von einer Telefonkonferenz und einem Webcast um 8:45 Uhr ET. Arbutus ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung einer funktionellen Heilung für das chronische Hepatitis-B-Virus (cHBV) konzentriert und über eine Pipeline von Verbindungen verfügt, zu denen das RNAi-Therapeutikum imdusiran und der orale PD-L1-Inhibitor AB-101 gehören.
- None.
- None.
WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its third quarter 2024 financial results and corporate update for Wednesday, November 6, 2024. The schedule for the press release and conference call/webcast are as follows:
| • Q3 2024 Press Release: | Wednesday, November 6, 2024 at 7:30 a.m. ET |
| • Q3 2024 Conference Call/Webcast: | Wednesday, November 6, 2024 at 8:45 a.m. ET |
To dial-in for the conference call by phone, please register using the following link: Registration Link. A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.
An archived webcast will be available on the Arbutus website after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
FAQ
When will Arbutus Biopharma (ABUS) report Q3 2024 earnings?
What are the main drug candidates in Arbutus Biopharma's (ABUS) pipeline?
What is the therapeutic focus of Arbutus Biopharma (ABUS)?
